网络编辑平台

编辑出版

《中国临床医学》编辑部

  地址:上海市枫林路179号18号楼501室

  邮编:200032

  电话:021-60267570

  邮箱:(1)zglcyx@126.com; (2)zglcyxfb@126.com

作者园地

在线调查

您喜欢的投稿方式调查


相关下载

您所在位置:首页->过刊浏览->第19卷第2期


论著:窄谱中波紫外线对特应性皮炎患者外周血Th17细胞比例及IL 17A、IL 23的影响
Effects of Narrow Band Ultraviolet B on Th17 Percentage, IL 17A and IL 23 Levels in Patients with Atopic Dermatitis
马蕾 薛海波 管秀好 刘宇博 舒春梅 张玉杰 安荣真
点击:1281次 下载:0次
作者单位:滨州医学院附属医院
中文关键字:特应性皮炎;窄谱中波紫外线;Th17细胞
英文关键字:Atopic dermatitis; NB UVB; Th17 cells
中文摘要:目的:评价窄谱中波紫外线(narrow band ultraviolet B, NB UVB)治疗特应性皮炎(atopic dermatitis, AD)的临床疗效及其对外周血Th17细胞比例与IL 17A、IL 23含量的影响。方法:AD患者34例(研究组)采用NB UVB照射治疗,治疗前及治疗后应用疾病严重程度评分(scoring atopic dermatitis, SCORAD)判断疾病严重程度和视觉模拟标尺法(visual analogue scale,
VAS)评价瘙痒程度;采用流式细胞术检测照射治疗前后外周血单一核细胞(peripheral blood mononuclear cells, PBMC)中Th17细胞占CD4+T细胞的比例(Th17%),采用酶联免疫吸附试验检测血清中IL 17A、IL 23的含量;以30例健康志愿者作为对照组。结果:研究组经NB UVB照射治疗后总有效率达79.41%,SCORAD评分[(33.75±8.91)比(17.63±5.09), t=9.156, P<0.01]及VAS评分[(8.95±2.86)比(4.46±2.08), t=7.406, P<0.01]均较治疗前显著降低。治疗前,研究组PBMC中Th17%及血清中IL 17A、IL 23含量较对照组显著升高[Th17%:(1.37%±0.41%)比(0.53%±0.11%), t=11.392;IL 17A:(40.38±8.23)pg/mL比(17.74±2.43)pg/mL, t=15.310;IL 23:(54.25±9.29)pg/mL比(23.23±3.47)pg/mL, t=18.101, 均P<0.01];NB UVB照射治疗后上述3个指标较治疗前均显著降低[Th17%:(0.72±0.15)%, t=8.556;IL 17A:(22.18±4.48)pg/mL, t=12.131;IL 23:(25.41±4.12)pg/mL, t=18.012, P均<0.01]。结论:NB UVB照射对AD具有显著的临床疗效,NB UVB可下调外周血Th17比例与IL 17A、IL 23含量,这可能是NB UVB治疗AD的机制之一。
英文摘要:Objective:To investigate the efficacy of narrow band ultraviolet B(NB UVB) in atopic dermatitis(AD) patients and its effects on Th17 cell percentage, IL 17A and IL 23 concentrations in their peripheral blood. Methods: A total of 34 AD patients were treated with NB UVB and the clinical efficacy was evaluated by scoring atopic dermatitis(SCORAD) and visual analogue scale(VAS) before and after treatment. Flow cytometric analysis(FCM) was performed to detect the percentage of Th17 cells and the serum concentrations of IL 17A and IL 23 were measured by enzyme linked immunosorbent assay(ELISA). Thirty healthy persons were recruited as normal controls. Results: After NB UVB treatment, the total effective rate of AD patients was 79.41%, and both the SCORAD index and VAS index decreased significantly[SCORAD, (33.75±8.91) vs. (17.63±5.09), t=9.156; VAS, (8.95±2.86) vs. (4.46±2.08), t=7.406, both P<0.01). Compared with healthy controls, AD patients before treatment showed a significant increase in peripheral Th17 cell percentage[(1.37%±0.41%) vs. (0.53%±0.11%), t=11.392, P<0.01] and serum IL 17A concentration[(40.38±8.23)pg/mL vs. (17.74±2.43)pg/mL, t=15.310, P<0.01] and IL 23 concentration[(54.25±9.29)pg/mL vs. (23.23±3.47)pg/mL, t=18.101, P<0.01]. After NB UVB treatment, Th17 cell percentage [(0.72%±0.15%), t=8.556, P<0.01] and IL 17A concentration[(22.18±4.48)pg/mL, t=12.131, P<0.01] and IL 23 concentration[(25.41±4.12)pg/mL, t=18.012, P<0.01] in AD patients decreased significantly. Conclusions: NB UVB is a good therapy for patients with AD and it can decrease serum Th17 cell percentage and IL 17A and IL 23 concentrations.
读者评论

      读者ID: 密码:   
我要评论:
主办单位:复旦大学附属中山医院
联系地址:上海市枫林路179号18号楼501室 邮编:200032
联系电话:021-60267570 E-Mail:(1)zglcyx@126.com; (2)zglcyxfb@126.com
版权所有©2009-2010 《中国临床医学》杂志编辑部 沪ICP备1103249号
本系统由北京菲斯特诺科技有限公司设计开发
您是本站第1269991名访问者